Buolamwini Receives Maturation Grant
Dr. John K. Buolamwini was recently awarded a Maturation Grant by the University of Tennessee Research Foundation entitled "Enhancement of Anticancer Activity and Pharmacokinetic Studies of 1-Aryl-Pyrido[b]Indoles." The grant is intended to further advance the technology around this novel class of anticancer agents and to increase the potential for commercialization of the associated intellectual property. Dr. Bernd Meibohm serves as co-investigator on the project. Last Fall, Dr. Buolamwini had also received two R21 awards by the National Institutes of Health focusing on drug discovery projects for the treatment of cardiovascular disease and HIV.